Table 1.
Study | Area | Tumor type | Gender (male/female) | Age (year) | N | Research index |
---|---|---|---|---|---|---|
Chen 2013 | China | Esophageal cancer | 50/28 | 61.9 ± 8.48 | 78 | † |
He 2014 | China | Endometrial cancer | 87 | — | 87 | ‡ † |
Kim 2015 | Korea | Cervical cancer | 111 | 50.6 ± 1.59 | 111 | † |
Lv 2013 | China | Esophageal cancer | 56/37 | — | 93 | ‡ † |
Nie 2013 | China | Nasopharyngeal carcinoma | 109/51 | 46 | 160 | ‡ † § |
Takayuki 2013 | Japan | Non‐small cell lung cancer | 49/28 | — | 77 | † |
Wu 2014 | China | Colon cancer | 64/56 | — | 120 | † |
Liu 2013 | China | Non‐small cell lung cancer | 32/10 | — | 42 | ‡ |
Qiu 2014 | China | Ovarian cancer | 64 | — | 64 | † § |
Qiu 2015 | China | Ovarian cancer | 68 | — | 68 | § |
Yan2014 | China | Bladder cancer | 80/30 | — | 110 | § |
HOTAIR expression with lymph node metastasis in carcinoma tissue.
HOX antisense transcript RNA (HOTAIR) expression in para‐carcinoma, cancer or normal tissues.
HOTAIR expression in different pathologically graded carcinoma tissue.